Gebremariam TeweldeTesfaye
Department of Medical Microbiology and Immunology, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.
Int J Health Sci (Qassim). 2016 Jan;10(1):137-43.
Cervical cancer is the leading cause of cancer deaths among women in Ethiopia. This may be due to the high prevalence of high-risk human papillomavirus (HR-HPV) genotypes in the population. So far, few studies have been done that showed the presence of HR-HPV genotypes. The HR-HPV-16, -18, -52, -56, -31 and -58 were the most common genotypes reported in Ethiopia. The introduction of HPV vaccines in Ethiopia is likely to go a long way in reducing cervical cancer deaths. However, there are few challenges to the introduction of the vaccines. The target population for HPV vaccination is at the moment not well-defined. Besides, the current HPV vaccines confer only type-specific (HPV-16 and -18) immunity, leaving a small proportion of Ethiopian women unprotected against other HR-HPV genotypes such as 52, 56, 31 and 58. Thus, future HPV vaccines such as the nanovalent vaccine may be more useful to Ethiopia as they will protect women against more genotypes.
宫颈癌是埃塞俄比亚女性癌症死亡的主要原因。这可能是由于该国人群中高危型人乳头瘤病毒（HR-HPV）基因型的高流行率。到目前为止，很少有研究表明存在HR-HPV基因型。HR-HPV-16、-18、-52、-56、-31和-58是埃塞俄比亚报告的最常见基因型。在埃塞俄比亚引入HPV疫苗可能在很大程度上减少宫颈癌死亡。然而，疫苗的引入存在一些挑战。目前HPV疫苗的目标人群尚未明确界定。此外，目前的HPV疫苗仅提供型特异性（HPV-16和-18）免疫力，使得一小部分埃塞俄比亚女性无法抵御其他HR-HPV基因型，如52、56、31和58。因此，未来的HPV疫苗，如九价疫苗，可能对埃塞俄比亚更有用，因为它们将保护女性抵御更多基因型。
